On April 24, 2026 Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company"), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, reported a corporate update on its partnership-driven strategy to advance its pipeline and enhance shareholder value.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following the success of its joint venture with GMP Biotechnology, which contributed to a $249.0 million increase in the Company’s balance sheet for the most recent fiscal year through an independent third-party valuation, the Company is continuing to pursue additional partnerships that provide financial and commercialization support.

The Company believes this strategy enables the advancement of multiple drug candidates in parallel while maintaining a capital-efficient operating model, and represents an effective approach to unlocking the value of its robust intellectual property portfolio.

CEO Commentary

"Our joint venture strategy has demonstrated the ability to unlock value through strategic partnerships," said Dr. Vuong Trieu, Chairman and Chief Executive Officer of Oncotelic. "We believe this is the right strategy to unlock our robust portfolio of intellectual property at scale. We are currently in discussions with potential partners and are working to establish additional collaborations in the near term."

(Press release, Oncotelic, APR 24, 2026, View Source [SID1234664764])